Draper said today that it inked a 3-year collaboration deal with Pfizer (NYSE:PFE) to develop Draper’s microphysiological system technology. The ‘organ-on-a-chip’ system is designed to improve preclinical safety and model diseases more effectively.
The Cambridge, Mass.-based company’s miniature organ model enables researchers to measure tissue function and test potential new drug candidates. Draper and Pfizer will collaborate on 3 microphysiological systems – liver, vascular and gastrointestinal organs.
Get the full story at our sister site, Drug Delivery Business News.
The post Draper, Pfizer ink ‘organ-on-a-chip’ deal appeared first on MassDevice.
from MassDevice http://ift.tt/2hnN1Wo
Cap comentari:
Publica un comentari a l'entrada